1. Key Insights 2. Parainfluenza Virus Infection Market Overview at a Glance 2.1. Market Share (%) Distribution of Parainfluenza Virus Infection in 2017 2.2. Market Share (%) Distribution of Parainfluenza Virus Infection in 2028 3. Disease Background and Overview: Parainfluenza Virus Infection 3.1. Introduction 3.2. Serotypes 3.3. Common Symptoms 3.4. Molecular Biology 3.5. Pathogenesis and Immunology 3.6. Clinical Manifestations 3.7. Diagnosis 3.8. Diagnostic Guidelines 3.9. Treatment and prevention 4. Epidemiology and Patient Population: Key Findings 4.1. G8 Total Patient Population of Parainfluenza Virus Infection 4.2. G8 Total Diagnosed Patient Population of Parainfluenza Virus Infection 5. Country Wise-Epidemiology of Parainfluenza Virus Infection 5.1. Registries and Studies for HSCT 5.2. United States 5.2.1. Assumptions and Rationale 5.2.2. Parainfluenza Virus Infection Prevalent Population in the United States 5.2.3. Parainfluenza Virus Infection Diagnosed Prevalent Population in the United States 5.2.4. Parainfluenza Virus Infection based on the Serotypes Prevalent Population in the United States 5.2.5. Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in the United States 5.3. EU5 Countries 5.3.1. Assumptions and Rationale 5.4. Germany 5.4.1. Parainfluenza Virus Infection Prevalent Population in Germany 5.4.2. Parainfluenza Virus Infection Diagnosed Prevalent Population in Germany 5.4.3. Parainfluenza Virus Infection based on the Serotypes Prevalent Population in Germany 5.4.4. Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in Germany 5.5. France 5.5.1. Parainfluenza Virus Infection Prevalent Population in France 5.5.2. Parainfluenza Virus Infection Diagnosed Prevalent Population in France 5.5.3. Parainfluenza Virus Infection based on the Serotypes Prevalent Population in France 5.5.4. Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in France 5.6. Italy 5.6.1. Parainfluenza Virus Infection Prevalent Population in Italy 5.6.2. Parainfluenza Virus Infection Diagnosed Prevalent Population in Italy 5.6.3. Parainfluenza Virus Infection based on the Serotypes Prevalent Population in Italy 5.6.4. Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in Italy 5.7. Spain 5.7.1. Parainfluenza Virus Infection Prevalent Population in Spain 5.7.2. Parainfluenza Virus Infection Diagnosed Prevalent Population in Spain 5.7.3. Parainfluenza Virus Infection based on the Serotypes Prevalent Population in Spain 5.7.4. Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in Spain 5.8. United Kingdom 5.8.1. Parainfluenza Virus Infection Prevalent Population in the United Kingdom 5.8.2. Parainfluenza Virus Infection Diagnosed Prevalent Population in the United Kingdom 5.8.3. Parainfluenza Virus Infection based on the Serotypes Prevalent Population in the United Kingdom 5.8.4. Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in the United Kingdom 5.9. Japan 5.9.1. Assumptions and Rationale 5.9.2. Parainfluenza Virus Infection Prevalent Population in Japan 5.9.3. Parainfluenza Virus Infection Diagnosed Prevalent Population in Japan 5.9.4. Parainfluenza Virus Infection based on the Serotypes Prevalent Population in Japan 5.9.5. Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in Japan 5.10. China 5.10.1. Assumptions and Rationale 5.10.2. Parainfluenza Virus Infection Prevalent Population in China 5.10.3. Parainfluenza Virus Infection Diagnosed Prevalent Population in China 5.10.4. Parainfluenza Virus Infection based on the Serotypes Prevalent Population in China 5.10.5. Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in China 6. Unmet Needs 7. Emerging Drugs 7.1. Key Cross Competition 7.2. DAS181: Ansun Biopharma 7.2.1. Product Description 7.2.2. Other Development Activities 7.2.3. Clinical Development 7.2.4. Product Profile 8. Parainfluenza Virus Infection: G8 Countries Analysis 8.1. Key Findings 8.2. Market Size of Parainfluenza Virus Infection in the G8 countries 9. The United States Market Outlook 9.1. United States Market Size 9.1.1. Total Market size of Parainfluenza Virus Infection 9.1.2. Market Size by Therapies 10. EU-5 Countries: Market Outlook 10.1.1. Total Market size of Parainfluenza Virus Infection in Germany 10.1.2. Market Size by Therapies 10.2. France 10.2.1. Total Market Size of Parainfluenza Virus Infection 10.2.2. Market Size by Therapies 10.3. Italy 10.3.1. Total Market Size of Parainfluenza Virus Infection 10.3.2. Market Size by Therapies 10.4. Spain 10.4.1. Total Market Size of Parainfluenza Virus Infection 10.4.2. Market Size by Therapies 10.5. United Kingdom 10.5.1. Total Market Size of Parainfluenza Virus Infection 10.5.2. Market Size by Therapies 11. Japan: Market Outlook 11.1. Japan market Size 11.1.1. Total Market Size of Parainfluenza Virus Infection 11.1.2. Market Size by Therapies 12. China: Market Outlook 12.1. China Market Size 12.1.1. Total Market Size of Parainfluenza Virus Infection 12.1.2. Market Size by Therapies 13. Market Drivers 14. Market Barriers 15. Appendix 15.1. Report Methodology 16. DelveInsight Capabilities 17. Disclaimer 18. About DelveInsight

Table 1 Taxonomic classification of HPIV subtypes 1-4 within the Paramyxoviridae family Table 2 Characterization of HPIV common structural proteins Table 3 Total Population of Parainfluenza Virus Infection in the G8 (2017-2028) Table 4 Total Diagnosed Population of Parainfluenza Virus Infection in the G8 Countries (2017-2028) Table 5 Parainfluenza Virus Infection Prevalent Population in the United States (2017-2028) Table 6 Parainfluenza Virus Infection Diagnosed Prevalent Population in the United States (2017-2028) Table 7 Parainfluenza Virus Infection based on the Serotypes Prevalent Population in the United States (2017-2028) Table 8 Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in the United States (2017-2028) Table 9 Parainfluenza Virus Infection Prevalent Population in Germany (2017-2028) Table10 Parainfluenza Virus Infection Diagnosed Prevalent Population in Germany (2017-2028) Table11 Parainfluenza Virus Infection based on the Serotypes Prevalent Population in Germany (2017-2028) Table12 Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in Germany (2017-2028) Table13 Parainfluenza Virus Infection Prevalent Population in France (2017-2028) Table14 Parainfluenza Virus Infection Diagnosed Prevalent Population in France (2017-2028) Table15 Parainfluenza Virus Infection based on the Serotypes Prevalent Population in France (2017-2028) Table16 Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in France (2017-2028) Table17 Parainfluenza Virus Infection Prevalent Population in Italy (2017-2028) Table18 Parainfluenza Virus Infection Diagnosed Prevalent Population in Italy (2017-2028) Table19 Parainfluenza Virus Infection based on the Serotypes Prevalent Population in Italy (2017-2028) Table20 Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in Italy (2017-2028) Table21 Parainfluenza Virus Infection Prevalent Population in Spain (2017-2028) Table22 Parainfluenza Virus Infection Diagnosed Prevalent Population in Spain (2017-2028) Table23 Parainfluenza Virus Infection based on the Serotypes Prevalent Population in Spain (2017-2028) Table24 Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in Spain (2017-2028) Table25 Parainfluenza Virus Infection Prevalent Population in the United Kingdom (2017-2028) Table26 Parainfluenza Virus Infection Diagnosed Prevalent Population in the United Kingdom (2017-2028) Table27 Parainfluenza Virus Infection based on the Serotypes Prevalent Population in the United Kingdom (2017-2028) Table28 Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in the United Kingdom (2017-2028) Table29 Parainfluenza Virus Infection Prevalent Population in Japan (2017-2028) Table30 Parainfluenza Virus Infection Diagnosed Prevalent Population in Japan (2017-2028) Table31 Parainfluenza Virus Infection based on the Serotypes Prevalent Population in Japan (2017-2028) Table32 Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in Japan (2017-2028) Table33 Parainfluenza Virus Infection Prevalent Population in China (2017-2028) Table34 Parainfluenza Virus Infection Diagnosed Prevalent Population in China (2017-2028) Table35 Parainfluenza Virus Infection based on the Serotypes Prevalent Population in China (2017-2028) Table36 Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in China (2017-2028) Table37 Comparison of emerging drugs under development Table38 Clinical Trial Description Table39 G8 Countries Market Size of Parainfluenza Virus Infection in USD Million (2017-2028) Table40 United States Market Size of Parainfluenza Virus Infection, USD Million (2017-2028) Table41 Market size of Parainfluenza Virus Infection by therapies in the United States, in USD Million (2017-2028) Table42 Market Size of Parainfluenza Virus Infection in Germany, in USD Million (2017-2028) Table43 Market size of Parainfluenza Virus Infection by therapies in Germany, in USD Million (2017-2028) Table44 Market Size of Parainfluenza Virus Infection in France, in USD Million (2017-2028) Table45 Market size of Parainfluenza Virus Infection by therapies in France, in USD Million (2017-2028) Table46 Market Size of Parainfluenza Virus Infection in Italy, in USD Million (2017-2028) Table47 Market size of Parainfluenza Virus Infection by therapies in Italy, in USD Million (2017-2028) Table48 Market Size of Parainfluenza Virus Infection in Spain, in USD Million (2017-2028) Table49 Market size of Parainfluenza Virus Infection by therapies in Spain, in USD Million (2017-2028) Table50 Market Size of Parainfluenza Virus Infection in the UK, in USD Million (2017-2028) Table51 Market size of Parainfluenza Virus Infection by therapies in the United Kingdom, in USD Million (2017-2028) Table52 Market Size of Parainfluenza Virus Infection in Japan, in USD Million (2017-2028) Table53 Market size of Parainfluenza Virus Infection by therapies in Japan, in USD Million (2017-2028) Table54 Market Size of Parainfluenza Virus Infection in China, in USD Million (2017-2028) Table55 Market size of Parainfluenza Virus Infection by therapies in China, in USD Million (2017-2028) Figure 1 Symptoms of Parainfluenza Virus Infection Figure 2 Structure of Human Parainfluenza Virus serotypes 1 to 4 Figure 3 Cycle of attachment, fusion, and replication for Parainfluenza Viruses Figure 4 Pathogenesis and disease progression of HPIV associated Croup Figure 5 Total Patient Population of Parainfluenza Virus Infection in the G8 (2017-2028) Figure 6 Total Diagnosed Patient Population of Parainfluenza Virus Infection in the G8 (2017-2028) Figure 7 Parainfluenza Virus Infection Prevalent Population in the United States (2017-2028) Figure 8 Parainfluenza Virus Infection Diagnosed Prevalent Population in the United States (2017-2028) Figure 9 Parainfluenza Virus Infection based on the Serotypes Prevalent Population in the United States (2017-2028) Figure 10 Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in the United States (2017-2028) Figure 11 Parainfluenza Virus Infection Prevalent Population in Germany (2017-2028) Figure 12 Parainfluenza Virus Infection Diagnosed Prevalent Population in Germany (2017-2028) Figure 13 Parainfluenza Virus Infection based on the Serotypes Prevalent Population in Germany (2017-2028) Figure 14 Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in Germany (2017-2028) Figure 15 Parainfluenza Virus Infection Prevalent Population in France (2017-2028) Figure 16 Parainfluenza Virus Infection Diagnosed Prevalent Population in France (2017-2028) Figure 17 Parainfluenza Virus Infection based on the Serotypes Prevalent Population in France (2017-2028) Figure 18 Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in France (2017-2028) Figure 19 Parainfluenza Virus Infection Prevalent Population in Italy (2017-2028) Figure 20 Parainfluenza Virus Infection Diagnosed Prevalent Population in Italy (2017-2028) Figure 21 Parainfluenza Virus Infection based on the Serotypes Prevalent Population in Italy (2017-2028) Figure 22 Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in Italy (2017-2028) Figure 23 Parainfluenza Virus Infection Prevalent Population in Spain (2017-2028) Figure 24 Parainfluenza Virus Infection Diagnosed Prevalent Population in Spain (2017-2028) Figure 25 Parainfluenza Virus Infection based on the Serotypes Prevalent Population in Spain (2017-2028) Figure 26 Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in Spain (2017-2028) Figure 27 Parainfluenza Virus Infection Prevalent Population in the United Kingdom (2017-2028) Figure 28 Parainfluenza Virus Infection Diagnosed Prevalent Population in the United Kingdom (2017-2028) Figure 29 Parainfluenza Virus Infection based on the Serotypes Prevalent Population in the United Kingdom (2017-2028) Figure 30 Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in the United Kingdom (2017-2028) Figure 31 Parainfluenza Virus Infection Prevalent Population in Japan (2017-2028) Figure 32 Parainfluenza Virus Infection Diagnosed Prevalent Population in Japan (2017-2028) Figure 33 Parainfluenza Virus Infection based on the Serotypes Prevalent Population in Japan (2017-2028) Figure 34 Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in Japan (2017-2028) Figure 35 Parainfluenza Virus Infection Prevalent Population in China (2017-2028) Figure 36 Parainfluenza Virus Infection Diagnosed Prevalent Population in China (2017-2028) Figure 37 Parainfluenza Virus Infection based on the Serotypes Prevalent Population in China (2017-2028) Figure 38 Parainfluenza Virus Infection in Hematopoietic Stem Cell Transplant (HSCTs) Patients Prevalent Population in China (2017-2028) Figure 39 Unmet Needs of Parainfluenza Virus Infection Figure 40 G8 Counties Market Size of Parainfluenza Virus Infection in USD Million (2017-2028) Figure 41 Market Size of Parainfluenza Virus Infection in the United States, USD Millions (2017-2028) Figure 42 Market size of Parainfluenza Virus Infection by therapies in the US, in USD Million (2017-2028) Figure 43 Market Size of Parainfluenza Virus Infection in Germany, USD Million (2017-2028) Figure 44 Market Size of Parainfluenza Virus Infection by therapies, in Germany, in USD Million (2017-2028) Figure 45 Market Size of Parainfluenza Virus Infection in France, USD Million (2017-2028) Figure 46 Market Size of Parainfluenza Virus Infection by therapies, in France, in USD Million (2017-2028) Figure 47 Market Size of Parainfluenza Virus Infection in Italy, USD Million (2017-2028) Figure 48 Market Size of Parainfluenza Virus Infection by therapies in Italy, in USD Million (2017-2028) Figure 49 Market Size of Parainfluenza Virus Infection in Spain, USD Million (2017-2028) Figure 50 Market Size of Parainfluenza Virus Infection by therapies in Spain, in USD Million (2017-2028) Figure 51 Market Size of Parainfluenza Virus Infection in the UK, USD Million (2017-2028) Figure 52 Market Size of Parainfluenza Virus Infection by therapies in the UK, in USD Million (2017-2028) Figure 53 Market Size of Parainfluenza Virus Infection in Japan, USD Million (2017-2028) Figure 54 Market Size of Parainfluenza Virus Infection by therapies in Japan, in USD Million (2017-2028) Figure 55 Market Size of Parainfluenza Virus Infection in China, USD Million (2017-2028) Figure 56 Market Size of Parainfluenza Virus Infection by therapies in China, in USD Million (2017-2028) Figure 57 Market Drivers Figure 58 Market Barriers

1.Ansun Biopharma 2.NIAID 3.ModernaTX, Inc. And Others